First-in-human study of Imperial-developed drug shows early promise in patients with multiple myeloma Multiple myeloma is an aggressive type of cancer originating in the bone marrow, and often affects several areas of the body, such as the spine, skull, pelvis and ribs. Despite introduction of new treatments, the disease remains mostly incurable due to relapse, […]

The Imperial College Genomic Symposium, organised by the NIHR Imperial BRC Genomics Facility, is a one-day meeting focusing on Genomic Medicine. It brings together basic and translational scientists and researchers to facilitate networking and to promote the development of our Genomics community at Imperial. The scientific program will consist of short presentations from experts in […]

Imperial researchers have developed an Artificial Intelligence system that could be used to personalise the treatment of patients with sepsis in real time. The computational model, known as ‘AI Clinician’, learned the best individual treatment strategy from medical records of almost 100,000 sepsis patients, and provided recommendations that proved more reliable than decisions made by […]

Researchers from the NIHR Imperial BRC have helped unravel the genetic code of tuberculosis (TB), enabling doctors to tailor treatments to each individual patient. The study, published in the New England Journal of Medicine, may herald a quicker, more tailored treatment for the millions of people around the world living with tuberculosis worldwide. The research […]

Pre-clinical evaluation of a novel immunotherapy treatment developed by Imperial researchers demonstrated potent anti-cancer properties Immunotherapy is a personalised treatment where patient’s own immune cells are programmed to attack cancer cells. Immune cells called T cells are extracted from patient’s blood and are genetically manipulated to insert CAR (chimeric antigen receptor), which recognises cancer cells. […]